Washington, DC (UroToday.com) Jamie Marko from the NIH Clinical Center, Bethesda, MD discussed radiographic consideration prior to clinical trial enrollment. All pre-trial enrollment imaging for bladder cancer should be <4 wks prior to enrollment. Generally, >1cm cut-off for defining malignancy accepted. Always archive prior exams to refer if needed for unequivocal lesions. Defining progression should be used from RECIST criteria >1cm for new lesion, <1cm demonstrate >50% growth on 2 consecutive exams with >5mm absolute increase or if <1cm >50% growth on a single exam or if multifocal sites are considered a recurrent disease. Define the date of recurrence/progression when definition met and do NOT backdate. Together, all of these standards will help clinical trial enrollment and coalesce accurate radiographic endpoints to compare data.
Presented by: Jamie Marko, MD, Lead Physician, Ultrasound Section, Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, Maryland
Written by: Stephen B. Williams, MD, Medical Director for High Value Care; Chief of Urology, Associate Professor, Director of Urologic Oncology, Director Urologic Research, The University of Texas Medical Branch at Galveston, TX and Ashish M. Kamat, MD, Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 2019 Bladder Cancer Advocacy Network (BCAN) Think Tank August 8-10, 2019 – the Capital Hilton, Washington, DC, USA